Sandoz targets biosimilar growth and generic semaglutide expansion

Sandoz is shifting its strategic focus toward biosimilars, which have become a primary growth driver for the company. In the first half of 2026, biosimilars accounted for 33 percent of total revenue, reaching a new high. This growth is driven by the expiration of patents for various biological medicines, creating opportunities for competitive alternatives. While traditional generics face ongoing price pressure, biosimilar revenues have seen particularly strong increases in North America.

Following a significant stock rally—with shares up 28 percent since the start of the year and over 200 percent since the spin-off from Novartis—investors are looking toward an upcoming investor day on September 8. Key topics of interest include updates on mid-term goals and the company's expansion plans regarding generic semaglutide, the active ingredient used in popular diabetes and weight-loss medications like Novo Nordisk’s Ozempic and Wegovy.

Sandoz has already received approval in Brazil for its semaglutide product, Owozy, intended for Type 2 diabetes treatment, with sales expected to begin in the second half of the year. The company's recent market performance was also bolstered by the announcement of a cooperation with Shanghai Henlius Biotech.